english          中文

Dementia and Neurodegenerative diseases

The following Dementia and Neurodegenerative diseases studies are now recruiting in Nottinghamshire Healthcare NHS Foundation Trust.

AD-Genetics: Detecting Susceptibility Genes for Late-Onset Alzheimer’s disease.

Principal Investigator: Professor Julie Williams.

Study Summary: The aim of this research is to build a better understanding of the causes of Alzheimers Disease and attempt to provide a platform for the development of targeted treatments and preventions. Focusing on identifying rare genetic variants of moderate to strong effect observed in the coding regions of genes. We will perform a large, powerful study in which we compare 300,000 rare DNA variants from throughout the human genome, in 20,000 AD cases and 49,000 controls. Through sample collection and collaboration we will enrich our clinical samples to include 1000 individuals with early-onset AD. This group is more likely to have rare genetic changes of moderate to large effect on their development of disease.

Inclusion criteria:

  • Less than or equal to age 64 at onset (can be of any age at study entry)
  • Meets ADRDA/NINCDS criteria for diagnosis of probable AD
  • Willingness to provide a blood sample
  • Caucasian

Exclusion criteria:

  • Current major depressive episode, psychosis (not associated with AD), acute manic or depressive episode of bipolar disorder.
  • Current diagnosis of substance abuse or substance dependence

Lead Research Delivery Officer: Stephanie Kings, This email address is being protected from spambots. You need JavaScript enabled to view it., 07789 500129

This study can be accesses through the Join Dementia Research Website www.joindementiaresearch.nihr.ac.uk

Effective Home Support in Dementia Care

Study Summary: The aims of this project are to

  • Define approaches to home support (‘care packages’), currently operating within selected local authority areas in England, delivered to people with dementia/their carers.
  • Observe the operation of these approaches over time, and generate data that will be used to investigate the cost-effectiveness of these approaches to home support.

This is a questionnaire based observational study and interviews are carried out at baseline and then 6 months follow-up.

Inclusion Criteria:

  • Individuals who are 60 years of age and over, who have an informal carer who they may or may not live with later stage dementia, designated as ‘very confused’.
  • Received statutory assessment or formal review of their care needs within the last three months by a health or social care professional.
  • Receiving support at home and resident within Nottinghamshire County.

Exclusion Criteria:

  • Individuals who are under 60 years of age.
  • Mild dementia, e.g. in early stages.
  • Resident outside Nottinghamshire County.

Lead Research Delivery Officer: David Kelly, This email address is being protected from spambots. You need JavaScript enabled to view it. 07900 223135

ELAD study- Evaluating the effects of the novel GLP-1 analogue, Liraglutide, in patients with Alzheimer's disease (ELAD) study.

Principal Investigator: Kehinde Junaid

Study Summary: There is a connection between type 2 diabetes and Alzheimer's disease; people with type 2 diabetes are much more likely to develop Alzheimer's disease than healthy people of the same age group. Recently, a drug used to treat type 2 diabetes, called liraglutide, has shown promise for the treatment of Alzheimer's disease. In laboratory studies it improves symptoms of Alzheimer's and reduces the amount of amyloid plaques in the brain, a hallmark of the disease. In this study, the researchers are going to test the effect of Liraglutide in people with Alzheimer's disease, to see whether the drug has positive effects on brain function and cognition.

Inclusion criteria:

  • Male/female aged 50-85.
  • Capable of giving and capacity to give informed consent.
  • A carer who can act as a reliable study partner.
  • Diagnosis of probable Alzheimer's disease according to NIAAA criteria.
  • Mini-Mental State Examination (MMSE) score of =22.
  • Rosen Modified Hachinski Ischemic score =4.
  • On stable medication for 3months; on or off Cholinesterase inhibitors.
  • Fluency in English and evidence of adequate premorbid intellectual functioning.
  • Likely to be able to participate in all scheduled evaluations and complete all required tests.

For Exclusion criteria: contact the Research Delivery Officer for information.

Lead Research Delivery Officer: David Kelly, This email address is being protected from spambots. You need JavaScript enabled to view it., 07900 223135

This study can be accesses through the Join Dementia Research Website www.joindementiaresearch.nihr.ac.uk 


Journeying through Dementia

Study Summary: Journeying through Dementia (JtD) is a pragmatic, two-arm, parallel group, individually randomised controlled trial, intended to determine the benefit of an occupational therapy based self-management intervention compared to usual care for people in the early stages of dementia.
Groups of 8-12 participants randomised to the intervention arm will be invited to attend 12 weekly facilitated meetings at local venues. The group will be assisted by the facilitators to select, explore and engage with activities that are relevant to them. Each participant will also be offered four individual sessions with one of the facilitators where they will be encouraged to pursue personal goals.

Inclusion criteria:

  • People diagnosed with dementia for example Alzheimer’s disease, vascular dementia or mixed Alzheimer’s/vascular dementia.
  • A Mini Mental State Examination (MMSE) Score of 18 or more.
  • Can make informed decisions.
  • Living in the community or in sheltered accommodation, alone or with others.
  • Are able to converse and communicate in English.
  • Are willing to engage in a 12 week group self-management intervention.

Exclusion criteria:

  • People not diagnosed with a form of dementia.
  • Being in more moderate stages of dementia. Measured by having a MMSE score of less than 18
  • Is assessed as lacking capacity
  • Living in residential or nursing care.
  • Not able to converse or communicate in English.

Lead Research Delivery Officer: David Kelly, This email address is being protected from spambots. You need JavaScript enabled to view it.,  07900 223135

This study can be accesses through the Join Dementia Research Website